IDEAYA BIOSCIENCES
IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.
IDEAYA BIOSCIENCES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.ideayabio.com
Total Employee:
101+
Status:
Active
Contact:
(650)491-9600
Email Addresses:
[email protected]
Total Funding:
226.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
5AM Ventures
5AM Ventures investment in Series B - IDEAYA Biosciences
Roche Venture Fund
Roche Venture Fund investment in Series B - IDEAYA Biosciences
Canaan Partners
Canaan Partners investment in Series B - IDEAYA Biosciences
GV
GV investment in Series B - IDEAYA Biosciences
Boxer Capital
Boxer Capital investment in Series B - IDEAYA Biosciences
Perceptive Advisors
Perceptive Advisors investment in Series B - IDEAYA Biosciences
WuXi Healthcare Ventures
WuXi Healthcare Ventures investment in Series B - IDEAYA Biosciences
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - IDEAYA Biosciences
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - IDEAYA Biosciences
Driehaus Capital Management
Driehaus Capital Management investment in Series B - IDEAYA Biosciences
Key Employee Changes
Official Site Inspections
http://www.ideayabio.com Semrush global rank: 4.7 M Semrush visits lastest month: 2.04 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IDEAYA Biosciences"
About – IDEAYA Biosciences
Andres was previously at Pharmacyclics, Inc., (NASDAQ: PCYC) where he helped lead the organization’s finance and operations efforts in support of the successful launch of blockbuster …See details»
IDEAYA Biosciences Announces Leadership Updates in Research …
Nov 5, 2019 SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company …See details»
IDEAYA Biosciences - Crunchbase Company Profile
Contact Email [email protected] Phone Number (650)491-9600 IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA …See details»
IDEAYA Biosciences - LinkedIn
IDEAYA Biosciences Biotechnology Research South San Francisco, California 14,006 followers Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision ...See details»
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial …
Nov 18, 2024 Most importantly, Stu's proven track record in maximizing the commercial opportunity for several global blockbuster cancer treatments, such as Trodelvy ® and Opdivo …See details»
Investor Relations | IDEAYA Biosciences - Documents & Charters
Corporate Governance involves the processes and procedures used to manage the business affairs of a company and includes the structure and balance of power between the …See details»
IDEAYA Biosciences CEO and Key Executive Team | Craft.co
IDEAYA Biosciences's President, Chief Executive Officer and Director is Yujiro S. Hata. Other executives include Michael White, Chief Scientific Officer; Darrin M. Beaupre, Chief Medical …See details»
IDEAYA Biosciences
Nov 15, 2021 Target Catalysts IDE397 Phase 1 – Cohort Expansions (H1 2022) – GSK Option Package & Clinical Data Update (H1 2022) PARG Development Candidate Lead NominatedSee details»
Investor Relations | IDEAYA Biosciences - Investor …
Nov 11, 2024 IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.See details»
News Releases - IDEAYA Bio
SOUTH SAN FRANCISCO, Oct. 18, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the …See details»
News Releases - IDEAYA Bio
May 10, 2022 IDEAYA Biosciences Paul Stone Senior Vice President and Chief Financial Officer [email protected]. IDEAYA Biosciences, Inc. Condensed Statements of Operations …See details»
Careers – IDEAYA Biosciences
Passion and purpose are the principles that guide every aspect of our organization. We offer competitive compensation, including equity participation and a benefits package that rewards …See details»
News Releases - media.ideayabio.com
Sep 18, 2024 "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharmaceuticals and the FDA. He has developed extensive commercial and …See details»
News Releases - IDEAYA Bio
Nov 8, 2022 Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026; …See details»
Science – IDEAYA Biosciences
G enetic sequencing and protein profiling are increasingly available to patients, clinicians, and researchers, for example, through broad-based tumor-profiling diagnostic panels. These tumor …See details»
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical ...
Jun 25, 2024 First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ®, Gilead's Trop-2 directed antibody-drug conjugate (ADC); …See details»
Clinical Trials – IDEAYA Biosciences
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized …See details»
Newsroom | IDEAYA Biosciences - Newsroom
Nov 18, 2024 IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 …See details»
IDEAYA Announces Positive Interim Phase 2 Monotherapy …
Jul 8, 2024 "We are highly encouraged by the preliminary clinical efficacy and favorable safety profile observed with IDE397 at the 30mg once-a-day expansion dose, including multiple …See details»